Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of 3.64 billion. The enterprise value is 5.60 billion.
| Market Cap | 3.64B |
| Enterprise Value | 5.60B |
Important Dates
The last earnings date was Thursday, July 31, 2025.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 397.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 180.16M |
Valuation Ratios
The trailing PE ratio is 27.77.
| PE Ratio | 27.77 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 2.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.58 |
| P/OCF Ratio | 12.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.87, with an EV/FCF ratio of 23.97.
| EV / Earnings | 42.72 |
| EV / Sales | 1.98 |
| EV / EBITDA | 13.87 |
| EV / EBIT | 23.16 |
| EV / FCF | 23.97 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 1.75.
| Current Ratio | 1.11 |
| Quick Ratio | 0.46 |
| Debt / Equity | 1.75 |
| Debt / EBITDA | 5.07 |
| Debt / FCF | 9.18 |
| Interest Coverage | 0.93 |
Financial Efficiency
Return on equity (ROE) is 11.21% and return on invested capital (ROIC) is 4.48%.
| Return on Equity (ROE) | 11.21% |
| Return on Assets (ROA) | 2.90% |
| Return on Invested Capital (ROIC) | 4.48% |
| Return on Capital Employed (ROCE) | 7.41% |
| Revenue Per Employee | 752,731 |
| Profits Per Employee | 34,191 |
| Employee Count | 3,832 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.57 |
Taxes
| Income Tax | -45.50M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +199.17% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +199.17% |
| 50-Day Moving Average | 4.01 |
| 200-Day Moving Average | 10.60 |
| Relative Strength Index (RSI) | 72.30 |
| Average Volume (20 Days) | 503 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of 2.88 billion and earned 131.02 million in profits. Earnings per share was 0.33.
| Revenue | 2.88B |
| Gross Profit | 1.76B |
| Operating Income | 257.53M |
| Pretax Income | 85.53M |
| Net Income | 131.02M |
| EBITDA | 422.89M |
| EBIT | 257.53M |
| Earnings Per Share (EPS) | 0.33 |
Balance Sheet
The company has 141.76 million in cash and 2.14 billion in debt, giving a net cash position of -2.00 billion.
| Cash & Cash Equivalents | 141.76M |
| Total Debt | 2.14B |
| Net Cash | -2.00B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.22B |
| Book Value Per Share | 3.07 |
| Working Capital | 173.49M |
Cash Flow
In the last 12 months, operating cash flow was 286.68 million and capital expenditures -53.16 million, giving a free cash flow of 233.52 million.
| Operating Cash Flow | 286.68M |
| Capital Expenditures | -53.16M |
| Free Cash Flow | 233.52M |
| FCF Per Share | n/a |
Margins
Gross margin is 60.93%, with operating and profit margins of 8.93% and 4.54%.
| Gross Margin | 60.93% |
| Operating Margin | 8.93% |
| Pretax Margin | 2.97% |
| Profit Margin | 4.54% |
| EBITDA Margin | 14.66% |
| EBIT Margin | 8.93% |
| FCF Margin | 8.10% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.02% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.60% |
| FCF Yield | 6.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 1.16 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 7 |